UCB SA (UCB.BR) Stock Fundamental Analysis
Europe - Euronext Brussels - EBR:UCB - BE0003739530 - Common Stock
233 EUR
+3.4 (+1.48%)
We assign a fundamental rating of 6 out of 10 to UCB. UCB was compared to 54 industry peers in the Pharmaceuticals industry. UCB has an average financial health and profitability rating. UCB is not priced too expensively while it is growing strongly. Keep and eye on this one! With these ratings, UCB could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
UCB had positive earnings in the past year.
In the past year UCB had a positive cash flow from operations.
Each year in the past 5 years UCB has been profitable.
UCB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
UCB has a Return On Assets of 7.75%. This is comparable to the rest of the industry: UCB outperforms 59.26% of its industry peers.
The Return On Equity of UCB (13.76%) is comparable to the rest of the industry.
Looking at the Return On Invested Capital, with a value of 11.63%, UCB is in line with its industry, outperforming 59.26% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for UCB is significantly below the industry average of 14.51%.
The last Return On Invested Capital (11.63%) for UCB is above the 3 year average (4.35%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.75% | ||
| ROE | 13.76% | ||
| ROIC | 11.63% |
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
1.3 Margins
The Profit Margin of UCB (19.45%) is better than 74.07% of its industry peers.
In the last couple of years the Profit Margin of UCB has remained more or less at the same level.
UCB's Operating Margin of 26.58% is fine compared to the rest of the industry. UCB outperforms 68.52% of its industry peers.
UCB's Operating Margin has declined in the last couple of years.
With a decent Gross Margin value of 73.38%, UCB is doing good in the industry, outperforming 62.96% of the companies in the same industry.
In the last couple of years the Gross Margin of UCB has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.58% | ||
| PM (TTM) | 19.45% | ||
| GM | 73.38% |
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), UCB is creating some value.
Compared to 1 year ago, UCB has about the same amount of shares outstanding.
Compared to 5 years ago, UCB has more shares outstanding
Compared to 1 year ago, UCB has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 5.01 indicates that UCB is not in any danger for bankruptcy at the moment.
The Altman-Z score of UCB (5.01) is better than 77.78% of its industry peers.
The Debt to FCF ratio of UCB is 2.43, which is a good value as it means it would take UCB, 2.43 years of fcf income to pay off all of its debts.
UCB has a Debt to FCF ratio of 2.43. This is in the better half of the industry: UCB outperforms 74.07% of its industry peers.
A Debt/Equity ratio of 0.29 indicates that UCB is not too dependend on debt financing.
UCB has a better Debt to Equity ratio (0.29) than 62.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | 2.43 | ||
| Altman-Z | 5.01 |
ROIC/WACC1.51
WACC7.68%
2.3 Liquidity
UCB has a Current Ratio of 1.35. This is a normal value and indicates that UCB is financially healthy and should not expect problems in meeting its short term obligations.
UCB has a Current ratio (1.35) which is comparable to the rest of the industry.
A Quick Ratio of 1.01 indicates that UCB should not have too much problems paying its short term obligations.
UCB has a Quick ratio (1.01) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.35 | ||
| Quick Ratio | 1.01 |
3. Growth
3.1 Past
UCB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 75.41%, which is quite impressive.
The Earnings Per Share has been decreasing by -0.86% on average over the past years.
Looking at the last year, UCB shows a very strong growth in Revenue. The Revenue has grown by 25.56%.
The Revenue has been growing slightly by 4.60% on average over the past years.
EPS 1Y (TTM)75.41%
EPS 3Y-8.45%
EPS 5Y-0.86%
EPS Q2Q%68.9%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%24.94%
3.2 Future
UCB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.74% yearly.
UCB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.52% yearly.
EPS Next Y54.7%
EPS Next 2Y43.27%
EPS Next 3Y38.39%
EPS Next 5Y29.74%
Revenue Next Year23.1%
Revenue Next 2Y18.69%
Revenue Next 3Y17.23%
Revenue Next 5Y14.52%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 36.29, the valuation of UCB can be described as expensive.
UCB's Price/Earnings is on the same level as the industry average.
UCB is valuated rather expensively when we compare the Price/Earnings ratio to 25.45, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 22.80, which indicates a rather expensive current valuation of UCB.
Based on the Price/Forward Earnings ratio, UCB is valued a bit more expensive than 61.11% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 34.46. UCB is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.29 | ||
| Fwd PE | 22.8 |
4.2 Price Multiples
UCB's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. UCB is more expensive than 62.96% of the companies in the same industry.
UCB's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 38.25 | ||
| EV/EBITDA | 18.37 |
4.3 Compensation for Growth
UCB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of UCB may justify a higher PE ratio.
A more expensive valuation may be justified as UCB's earnings are expected to grow with 38.39% in the coming years.
PEG (NY)0.66
PEG (5Y)N/A
EPS Next 2Y43.27%
EPS Next 3Y38.39%
5. Dividend
5.1 Amount
UCB has a yearly dividend return of 0.42%, which is pretty low.
UCB's Dividend Yield is comparable with the industry average which is at 3.01.
With a Dividend Yield of 0.42, UCB pays less dividend than the S&P500 average, which is at 2.45.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.42% |
5.2 History
The dividend of UCB has a limited annual growth rate of 2.45%.
Dividend Growth(5Y)2.45%
Div Incr Years6
Div Non Decr Years6
5.3 Sustainability
UCB pays out 19.82% of its income as dividend. This is a sustainable payout ratio.
The dividend of UCB is growing, but earnings are growing more, so the dividend growth is sustainable.
DP19.82%
EPS Next 2Y43.27%
EPS Next 3Y38.39%
EBR:UCB (11/21/2025, 7:00:00 PM)
233
+3.4 (+1.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners40.07%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap45.32B
Revenue(TTM)6.85B
Net Income(TTM)1.33B
Analysts76
Price Target257.95 (10.71%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.42% |
Yearly Dividend1.36
Dividend Growth(5Y)2.45%
DP19.82%
Div Incr Years6
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.01%
PT rev (3m)15.07%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)2.2%
EPS NY rev (3m)3.85%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.35%
Revenue NY rev (3m)6.79%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.29 | ||
| Fwd PE | 22.8 | ||
| P/S | 6.62 | ||
| P/FCF | 38.25 | ||
| P/OCF | 28.76 | ||
| P/B | 4.68 | ||
| P/tB | 41.69 | ||
| EV/EBITDA | 18.37 |
EPS(TTM)6.42
EY2.76%
EPS(NY)10.22
Fwd EY4.39%
FCF(TTM)6.09
FCFY2.61%
OCF(TTM)8.1
OCFY3.48%
SpS35.21
BVpS49.78
TBVpS5.59
PEG (NY)0.66
PEG (5Y)N/A
Graham Number84.8
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.75% | ||
| ROE | 13.76% | ||
| ROCE | 13.73% | ||
| ROIC | 11.63% | ||
| ROICexc | 13.71% | ||
| ROICexgc | 58.2% | ||
| OM | 26.58% | ||
| PM (TTM) | 19.45% | ||
| GM | 73.38% | ||
| FCFM | 17.3% |
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
ROICexc(3y)4.85%
ROICexc(5y)7.22%
ROICexgc(3y)28.31%
ROICexgc(5y)48.18%
ROCE(3y)5.15%
ROCE(5y)7.49%
ROICexgc growth 3Y-25.87%
ROICexgc growth 5Y-16.2%
ROICexc growth 3Y-19.14%
ROICexc growth 5Y-14.38%
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
F-Score9
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | 2.43 | ||
| Debt/EBITDA | 1.15 | ||
| Cap/Depr | 61.48% | ||
| Cap/Sales | 5.71% | ||
| Interest Coverage | 16.4 | ||
| Cash Conversion | 64.17% | ||
| Profit Quality | 88.96% | ||
| Current Ratio | 1.35 | ||
| Quick Ratio | 1.01 | ||
| Altman-Z | 5.01 |
F-Score9
WACC7.68%
ROIC/WACC1.51
Cap/Depr(3y)52.98%
Cap/Depr(5y)82.03%
Cap/Sales(3y)5.99%
Cap/Sales(5y)6.61%
Profit Quality(3y)131.69%
Profit Quality(5y)119.05%
High Growth Momentum
Growth
EPS 1Y (TTM)75.41%
EPS 3Y-8.45%
EPS 5Y-0.86%
EPS Q2Q%68.9%
EPS Next Y54.7%
EPS Next 2Y43.27%
EPS Next 3Y38.39%
EPS Next 5Y29.74%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%24.94%
Revenue Next Year23.1%
Revenue Next 2Y18.69%
Revenue Next 3Y17.23%
Revenue Next 5Y14.52%
EBIT growth 1Y258.97%
EBIT growth 3Y-13.71%
EBIT growth 5Y-5.23%
EBIT Next Year150.43%
EBIT Next 3Y58.09%
EBIT Next 5Y40.4%
FCF growth 1Y91.13%
FCF growth 3Y-4.61%
FCF growth 5Y9.37%
OCF growth 1Y61.64%
OCF growth 3Y-7.18%
OCF growth 5Y7.09%
UCB SA / UCB.BR FAQ
What is the fundamental rating for UCB stock?
ChartMill assigns a fundamental rating of 6 / 10 to UCB.BR.
What is the valuation status of UCB SA (UCB.BR) stock?
ChartMill assigns a valuation rating of 4 / 10 to UCB SA (UCB.BR). This can be considered as Fairly Valued.
Can you provide the profitability details for UCB SA?
UCB SA (UCB.BR) has a profitability rating of 6 / 10.
How financially healthy is UCB SA?
The financial health rating of UCB SA (UCB.BR) is 6 / 10.
How sustainable is the dividend of UCB SA (UCB.BR) stock?
The dividend rating of UCB SA (UCB.BR) is 4 / 10 and the dividend payout ratio is 19.82%.